{"filings":[{"id":1176337,"accession_number":"0001472375-26-000172","cik":1357878,"company_name":"REGENEREX PHARMA, INC.","ticker":"RGPX","form_type":"8-K","filed_at":"2026-06-18T21:39:00+00:00","items":["8.01","9.01"],"status":"ready","headline":"Regenerex Pharma sues former CFO's Optimize Health for overbilling, breach of contract","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Filed lawsuit against Optimize Health Partners (owned by ex-CFO Kenneth Perry) for breach of software license agreement.","Alleges overbilling of ~$37,285 and unauthorized markups on invoices totaling ~$136,056 paid.","Claims failure to deposit software source code escrow materials and to maintain required insurance.","Seeks monetary damages, accounting, declaratory judgment, and injunctive relief to protect access to systems.","Defendant Perry denies allegations and has indicated intention to defend; case is in preliminary stages."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":0.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":994596,"accession_number":"0001472375-26-000167","cik":1357878,"company_name":"REGENEREX PHARMA, INC.","ticker":"RGPX","form_type":"8-K","filed_at":"2026-06-11T17:52:03+00:00","items":["5.02","9.01"],"status":"ready","headline":"Regenerex sues former CFO Perry for alleged $55K overpayments, $37K overcharges, stock theft","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Complaint filed June 5, 2026, in Smith County Chancery Court (Case No. 2026-CV-8813).","Alleges former CFO Perry caused unauthorized payroll overpayments totaling ~$55,200 over six months.","Perry's company Optimize Health overbilled $136,056; includes alleged 30% administrative fee of ~$37,285.","Perry authorized 25,000 shares of common stock to a trust without board approval, then canceled.","Company says Perry's conduct caused delayed Form 10-K filing and substantial audit/remediation costs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":0.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92393,"accession_number":"0001472375-26-000133","cik":1357878,"company_name":"REGENEREX PHARMA, INC.","ticker":"RGPX","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Regenerex Pharma terminates CFO Kenneth Perry for cause; appoints Don E. Ray as interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kenneth Perry placed on administrative suspension with pay on March 31, 2026.","Board determined Perry's conduct constituted material breach and 'Cause' under employment agreement; termination effective May 2, 2026.","Don E. Ray appointed Interim CFO effective April 1, 2026 for an initial 90-day term.","CEO Greg Pilant recused himself from deliberations; independent board made decision."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":0.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92392,"accession_number":"0001472375-26-000113","cik":1357878,"company_name":"REGENEREX PHARMA, INC.","ticker":"RGPX","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":[],"status":"ready","headline":"Regenerex Pharma suspends CFO Kenneth Perry; appoints Don E. Ray as interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Kenneth Perry placed on administrative suspension leave with pay, effective March 31, 2026, due to concerns over compliance, financial oversight, governance, and internal controls.","Don E. Ray appointed Interim CFO effective April 1, 2026, for an initial 90-day term at an annual salary of $150,000.","Board reassigned Perry's duties to interim CFO; review of the concerns is ongoing with no final determinations yet."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":0.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119467,"accession_number":"0001472375-25-000130","cik":1357878,"company_name":"REGENEREX PHARMA, INC.","ticker":"RGPX","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["5.03"],"status":"ready","headline":"Regenerex Pharma changes fiscal year end from March 31 to December 31","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved fiscal year change effective September 22, 2025.","New fiscal year end will be December 31, replacing March 31.","Transition report on Form 10-K for April 1, 2025 to December 31, 2025 to be filed.","No other amendments to bylaws or articles were disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":0.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136034,"accession_number":"0001472375-25-000103","cik":1357878,"company_name":"REGENEREX PHARMA, INC.","ticker":"RGPX","form_type":"8-K","filed_at":"2025-09-03T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Regenerex Pharma enters exclusive collagen supply deal with Holista; minimum purchases ramp to $9M/yr","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive worldwide rights to Holista's ovine collagen for wound care; initial focus on U.S. market.","Minimum purchase commitments: $50k in 2025, $3M in 2026, $6M in 2027, $9M annually from 2028.","Regenerex to fund clinical studies and FDA regulatory approvals for advanced wound care products.","Joint collaboration on nano-collagen applications with shared IP ownership.","Agreement runs for life of patents; can be terminated on 90 days' notice or for breach/insolvency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":0.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136033,"accession_number":"0001472375-25-000083","cik":1357878,"company_name":"REGENEREX PHARMA, INC.","ticker":"RGPX","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Regenerex Pharma enters licensing deal with Holista for ovine collagen wound care","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive rights to use Holista's ovine collagen in wound care and distribution in USA.","Ovine nano-collagen integrated into Regenerex's QBx™ technology to accelerate deep tissue regeneration.","Collagen sourced from ethically raised, disease-free Australian sheep; avoids mad cow disease concerns.","CEO Greg Pilant says ovine collagen is safer and more culturally acceptable than bovine/porcine sources.","Agreement targets advanced wound care solutions for U.S. and international markets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":0.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153064,"accession_number":"0001472375-25-000037","cik":1357878,"company_name":"REGENEREX PHARMA, INC.","ticker":"RGPX","form_type":"8-K","filed_at":"2025-04-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Regenerex Pharma appoints Kenneth Perry as CFO; Brent Wilson resigns effective March 31, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kenneth W. Perry appointed CFO effective March 31, 2025; 39 years of healthcare finance experience.","Brent Wilson resigned as CFO on March 31, 2025, citing personal reasons.","Perry holds an MBA in Finance from Mississippi State and a BS in Accounting from Tennessee Tech.","Previously served as Division CFO for HCA and founded Lasis Healthcare; multiple award-winning CFO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":0.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188847,"accession_number":"0001472375-24-000106","cik":1357878,"company_name":"REGENEREX PHARMA, INC.","ticker":"RGPX","form_type":"8-K","filed_at":"2024-12-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"RegeneRx Pharma announces CFO resignation and appointments of new CFO, Secretary, and board member","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Deborah Pilant resigned as CFO, Secretary/Treasurer, and board director effective Dec 6, 2024, due to retirement.","Brent Wilson appointed CFO; CPA with 30 years experience, previously at KPMG, effective Dec 6, 2024.","Dr. Lee Ori appointed Secretary/Treasurer for the coming year; currently serves as a board director.","J. Kenneth Hazen appointed to the board; President/CEO of CTSI-Global, recognized in logistics and supply chain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":0.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276450,"accession_number":"0001472375-23-000134","cik":1357878,"company_name":"REGENEREX PHARMA, INC.","ticker":"RGPX","form_type":"8-K","filed_at":"2023-09-28T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Regenerex Pharma announces 95% wound closure rate and Q4 2023 manufacturing plans","summary_kind":"llm","event_type":"other","confidence":"medium","bullets":["Products Xcellderma and Accelerex target chronic wounds via proprietary QBx ingredient.","Claims 95% of chronic wounds show 100% closure within 90 days in clinical evaluations.","Manufacturing to begin in Q4 2023 at facility in Memphis, TN.","No specific management officer or director names were provided in the update.","Products are FDA-cleared or OTC; Accelerex is a prescription-only combination device."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":0.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":350643,"accession_number":"0001472375-22-000082","cik":1357878,"company_name":"REGENEREX PHARMA, INC.","ticker":"RGPX","form_type":"8-K","filed_at":"2022-08-26T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Regenerex Pharma announces CFO, director resignations; appoints Lee Ori to board, Deborah Pilant as CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Irene Getty resigned as CFO, Bruce Sellars resigned from board, Byron Striloff resigned as officer, all effective Aug 25, 2022.","Dr. Lee Ori appointed to board effective Aug 25; he also serves as COO. Background: pharmacy doctorate, Eli Lilly, multiple pharmacist licenses.","Deborah L. Pilant appointed CFO effective Aug 25; already serving as Secretary/Treasurer and Director. Background in education, construction, sales.","No reason given for departures or any financial impact disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":0.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":387171,"accession_number":"0001472375-22-000008","cik":1357878,"company_name":"REGENEREX PHARMA, INC.","ticker":"RGPX","form_type":"8-K","filed_at":"2022-01-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"RegeneRex Pharma appoints Troy Thuet as COO; Dr. Lee Ori becomes Chief R&D Officer","summary_kind":"llm","event_type":"leadership","confidence":"medium","bullets":["Troy Thuet appointed COO effective Jan 14, 2022; over 15 years of managerial and executive experience.","Dr. Lee Ori transitions from COO to Chief R&D Officer; holds PharmD from Auburn, formerly at Eli Lilly.","No departure or compensation details disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":0.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":405107,"accession_number":"0001472375-21-000139","cik":1357878,"company_name":"REGENEREX PHARMA, INC.","ticker":"RGPX","form_type":"8-K","filed_at":"2021-11-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Peptide Technologies names Gregory Pilant CEO/Chairman, Deborah Pilant Secretary/Treasurer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Gregory P. Pilant appointed CEO and Chairman of the Board effective Nov 16, 2021; Deborah L. Pilant appointed Secretary/Treasurer.","Dennis Cox and Irene Getty resigned from Board of Directors effective Nov 16, 2021.","Bruce Sellars resigned as CEO but remains on Board; Byron Striloff resigned as President effective Nov 16, 2021.","Dr. Lee Ori appointed as Chief Operating Officer effective Nov 16, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":0.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":405106,"accession_number":"0001472375-21-000133","cik":1357878,"company_name":"REGENEREX PHARMA, INC.","ticker":"RGPX","form_type":"8-K","filed_at":"2021-11-18T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Peptide Technologies acquires wound healing IP for 150M shares and $10M deferred cash","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired Wound Healing Technology Platform from Gregory P. Pilant and Deborah L. Pilant for 150M restricted common shares and $10M deferred cash.","Cash payment of $10M to be funded from future revenue or investment, due within 60 months, with no interest.","Closing deadline set for November 25, 2021 (within 10 days of signing on November 15, 2021).","Technology platform includes drug candidates and biological solutions for chronic wound care in humans."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":0.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}